STOCK TITAN

Keen Vision (KVAC) pushes Medera merger agreement target to April 30

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Keen Vision Acquisition Corporation reported that it amended its binding letter of intent with Medera Inc. and its subsidiary Novoheart Group Limited. The amendment moves the target date to sign a new replacement merger agreement from April 10, 2026 to April 30, 2026.

The prior merger agreement dated September 3, 2024 had already been terminated and replaced by this letter of intent. The parties continue to use their best efforts to finalize and execute the replacement merger agreement by the new deadline.

Positive

  • None.

Negative

  • None.
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
New replacement merger agreement deadline April 30, 2026 Amendment to letter of intent between Keen Vision, Medera Inc., and Novoheart Group Limited
Prior replacement merger agreement deadline April 10, 2026 Original deadline under the binding letter of intent before amendment
Original merger agreement date September 3, 2024 Terminated merger agreement replaced by the binding letter of intent
Material Definitive Agreement regulatory
"Item 1.01 Entry into a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
binding letter of intent financial
"entered into a binding letter of intent (the “LOI”) with Medera Inc."
A binding letter of intent is a short written agreement in which parties formally commit to the main terms of a proposed transaction — such as price, timeline and key conditions — before the full contract is completed. It matters to investors because it raises the chance the deal will actually happen and can change a company’s value and risk profile, much like a signed down-payment that holds buyers and sellers to core promises while final paperwork is finished.
Replacement Merger Agreement financial
"to negotiate and execute a replacement merger agreement (“Replacement Merger Agreement”)"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
false 0001889983 00-0000000 0001889983 2026-02-26 2026-02-26 0001889983 KVACW:UnitsEachConsistingOfOneOrdinaryShareAndOneRedeemableWarrantToAcquireOneOrdinaryShareMember 2026-02-26 2026-02-26 0001889983 KVACW:OrdinaryShares0.0001ParValueMember 2026-02-26 2026-02-26 0001889983 KVACW:WarrantsEachExercisableForOneOrdinaryShareAtExercisePriceOf11.50Member 2026-02-26 2026-02-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

February 26, 2026

Date of Report (Date of earliest event reported)

 

KEEN VISION ACQUISITION CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

British Virgin Islands   001-41753   n/a
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)

 

37 Greenbriar Drive

Summit, New Jersey

  07901
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (203) 609-1394

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Units, each consisting of one ordinary share and one redeemable warrant to acquire one ordinary share   KVACU   The Nasdaq Stock Market LLC
Ordinary Shares, $0.0001 par value   KVAC   The Nasdaq Stock Market LLC
Warrants, each exercisable for one ordinary share at an exercise price of $11.50   KVACW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

As previously disclosed, Keen Vision Acquisition Corporation, a British Virgin Islands business company limited by shares, (the “Parent”), entered into a binding letter of intent (the “LOI”) with Medera Inc., a Cayman Islands exempted company (the “Company”), and Novoheart Group Limited, a British Virgin Islands company and wholly owned subsidiary of the Company (“NVH”). The LOI replaces the prior Merger Agreement dated September 3, 2024, which was terminated concurrently with execution of the LOI pursuant to a mutual release agreement entered into by the parties.

 

Under the LOI, Parent and NVH have agreed to use their best efforts to negotiate and execute a replacement merger agreement (“Replacement Merger Agreement”) no later than April 10, 2026. The parties entered into an amendment to the LOI dated April 14, 2026, pursuant to which the parties agreed to extend the deadline for execution of the Replacement Merger Agreement from April 10, 2026 to April 30, 2026.

 

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: April 15, 2026 Keen Vision Acquisition Corporation
     
  By: /s/ WONG, Kenneth Ka Chun
  Name:  WONG, Kenneth Ka Chun
  Title: Chief Executive Officer

 

2

 

FAQ

What did Keen Vision Acquisition Corporation (KVAC) change in its Medera deal timeline?

Keen Vision Acquisition Corporation extended the target date to sign a replacement merger agreement with Medera Inc. and Novoheart Group Limited from April 10, 2026 to April 30, 2026, giving the parties more time to negotiate final transaction terms under their existing letter of intent.

What is the relationship between Keen Vision (KVAC), Medera Inc., and Novoheart Group Limited?

Keen Vision Acquisition Corporation is pursuing a business combination with Medera Inc., a Cayman Islands exempted company, and its wholly owned subsidiary Novoheart Group Limited. The parties are working under a binding letter of intent to finalize a replacement merger agreement governing the proposed transaction structure.

What happened to the original merger agreement between KVAC and Medera Inc.?

The original merger agreement dated September 3, 2024 was terminated through a mutual release among the parties. It was replaced by a binding letter of intent, under which Keen Vision, Medera Inc., and Novoheart Group Limited are now working to negotiate and sign a new replacement merger agreement.

What is the new deadline to execute the replacement merger agreement for KVAC?

Under the April 14, 2026 amendment to the letter of intent, Keen Vision, Medera Inc., and Novoheart Group Limited agreed to extend the deadline to execute the replacement merger agreement to April 30, 2026, shifting it from the earlier April 10, 2026 target date.

Why is Keen Vision Acquisition Corporation’s Form 8-K filing important for KVAC investors?

The filing informs investors that Keen Vision’s potential business combination with Medera Inc. remains active but is still in negotiation. Extending the deadline to April 30, 2026 signals the parties are continuing discussions rather than abandoning the transaction framework established by their binding letter of intent.

Filing Exhibits & Attachments

4 documents